Awakn Life Sciences to Commence Trading on the OTC Market on July 26, 2021 Under the Symbol ‘AWKNF’ Post published:July 26, 2021 Post category:Press Release
Awakn Life Sciences Initiates Research Program to Further Develop Ketamine-Assisted Therapies for Treating Addiction Post published:July 14, 2021 Post category:Press Release
Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline Post published:July 7, 2021 Post category:Press Release
Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications Post published:June 28, 2021 Post category:Press Release
Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer Post published:June 24, 2021 Post category:Press Release
Awakn Life Sciences to Commence Trading on the NEO Exchange under the Symbol ‘AWKN’ Post published:June 23, 2021 Post category:Press Release
Awakn Life Sciences Corp. Announces Completion Of Reverse Takeover Transaction, Release From Escrow Of Private Placement Proceeds, And Final Approval For Listing On Neo Exchange Post published:June 17, 2021 Post category:Press Release
Awakn Life Sciences Completes Previously Announced Private Placement For Gross Proceeds Of $8.3 Million Post published:June 8, 2021 Post category:Press Release
Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec as Research Partner and Addiction Expert, Prof. David Nutt, as Program Lead Post published:April 27, 2021 Post category:Press Release
Awakn launches Digital unit and signs agreement with the University of Exeter Post published:April 12, 2021 Post category:Press Release